The First and Only Orally Disintegrating Prednisolone Tablet
  |
 |
|
 |
||
 |
||
| Indication | ||
Orapred ODT (prednisolone sodium phosphate orally disintegrating tablets) is a prescription drug product indicated for
the control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with
asthma or asthma caused by respiratory disorders. |
||
|
|
||
| Important Safety Information | ||
Do not break or use partial Orapred ODT tablets. Orapred ODT is contraindicated in patients with systemic fungal infections. Administration of live or live, attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids. Killed or inactivated vaccines may be administered, however, the response to such vaccines cannot be predicted. Immunization procedures may be undertaken in patients who are receiving corticosteroids as replacement therapy, e.g., for Addison’s disease. Orapred ODT may cause mood swings. Adverse effects of Orapred ODT include the following: endocrine (including development of cushingoid state, increased requirements for insulin or oral hypoglycemic agents in diabetic patients, manifestations of latent diabetes mellitus); fluid and electrolyte disturbances (including fluid retention, hypertension); gastrointestinal (including peptic ulcer with possible perforation and hemorrhage); increased appetite; and weight gain. |
||
| |
||
For additional safety information:
Click here to see the Orapred ODT full Prescribing Information. Click here for the Orapred OS full Prescribing Information. Privacy Policy / Legal Terms of Use Manufactured for Shionogi Inc. Florham Park, NJ 07932 by CIMA LABS INC., Eden Prairie, MN 55344 |
||
 © 2011 Shionogi Inc., Florham Park, NJ 07932 ORA-WEB-01 |
||